Academic institutions worldwide are increasingly adopting the clinical outcome assessments (COA) of steroid-toxicity that make up the STOX^® Suite from Steritas. To date, 26 academic licenses are in use across 30 clinical trials involving 5,412 patients in 12 countries.

Trials using Steritas’ COA span key geographies, with strong representation in the US (seven trials), the United Kingdom (six), and Turkey (four), alongside studies in Australia, Brazil, France, Germany, India, Japan, the Netherlands, Poland, and South Africa.

Institutions such as Stanford University, the Mayo Clinic, Beth Israel Deaconess, Hacettepe University, the University of Occupational and Environmental Health in Japan, and University College London are integrating Steritas instruments into high-quality academic research. Of particular note is the international diversity of participation and the breadth of disease indications, which reflect the universal relevance of steroid-toxicity measurement. These include asthma, systemic lupus erythematosus (SLE), lupus nephritis, juvenile idiopathic arthritis, inflammatory myopathies, ANCA-associated vasculitis, dermatomyositis, polymyalgia rheumatica, rheumatoid arthritis, and myasthenia gravis, among others.

Several influential clinicians are at the forefront of these trials. Professor Dedee Murrell (UNSW), a vocal advocate for measuring steroid-toxicity in autoimmune blistering diseases, continues to lead efforts to elevate dermatology standards. 

Dr Neelam Goyal (Stanford University) is similarly leveraging Steritas instruments in neurology, particularly for myasthenia gravis.

Dr Jane McDowell (Queen's University Belfast) remains instrumental in asthma research, with landmark studies highlighting the importance of early steroid tapering. 

At Massachusetts General Hospital, Dr Naomi Patel is applying Steritas tools in rheumatologic conditions, complementing efforts by Dr Melda Behap in Turkey, who is leading the charge in measuring steroid-toxicity experienced by patients visiting rheumatology outpatient clinics. 

Professor Clare Pain of the UK’s Alder Hey Children’s Hospital is applying the Steritas pGTI in the STAR-JIA trial, which aims to understand not only which steroid route is the most effective for treating inflammation in juvenile idiopathic arthritis but also if there are differences in the toxicities experienced by patients.

The expanding global footprint of Steritas' COAs in academic research underscores a collective shift toward quantifying and minimizing steroid-toxicity. To support these important efforts, Steritas welcomes applications for no-fee licenses for unfunded academic research. Academic licenses are accompanied by the same level of access and support as commercial licenses. 

As more clinicians and researchers adopt these tools, the potential to meaningfully transform patient care across autoimmune and inflammatory diseases becomes ever more tangible.

Unlock the STOX^®

Did you know about Steritas' support for unfunded academic research?

We welcome applications for no-fee academic licenses to the STOX Suite and access to the STOX Digital Platform.